← SynDRA
TALADEGIB
SynDRA canonical compound SYN0033802 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | SMO |
|---|
| Mechanism of action | Smoothened receptor antagonist |
|---|
All known targets
Mechanisms of action (all sources)
- Smoothened receptor antagonist
- SMO ANTAGONIST
- Smoothened homolog antagonist
- SMO MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- LY-2940680
- LY2940680
- LY 2940680
- UNII-QY8BWX1LJ5
- 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide
- QY8BWX1LJ5
- Taladegib (LY2940680)
- 4-fluoro-n-methyl-n-(1-(4-(1-methyl-1h-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)benzamide
- 4-Fluoro-N-Methyl-N-{1-[4-(1-Methyl-1h-Pyrazol-5-Yl)phthalazin-1-Yl]piperidin-4-Yl}-2-(Trifluoromethyl)benzamide
- Taladegib [USAN:INN]
- ENV-101
- taladegibum
- RefChem:932522
- DTXCID6077477
- MFCD21609264
- C26H24F4N6O
- Taladegib [INN]
- Taladegib (USAN/INN)
- TALADEGIB [USAN]
- TALADEGIB [WHO-DD]
- MLS006011066
- LY-2940680(Taladegib)
- orb1305194
- SCHEMBL2128615
- LY-2940680(Taladegib)?
- SCHEMBL29370217
- SCHEMBL29395144
- GTPL10333
- EX-A156
- GLXC-90370
- BDBM50545020
- NSC767896
- AKOS026674116
- CCG-269788
- CS-0459
- NSC-767896
- SB16504
- NCGC00263170-01
Look up TALADEGIB in the interactive SynDRA portal →